Inmune Bio Inc. · NASDAQ:INMB
Inmune Bio — Conference Presentation (October 2020)
13 slides from Inmune Bio's conference presentation, Oct 27, 2020
Slide 1: COVID-19 Review October 2020
www.roth.com Member: FINRA / SIPC 1 of 15 COVID - 19 Review October 2020
Slide 2: Forward Looking Statements
www.roth.com Member: FINRA / SIPC 2 of 15 Forward Looking Statements
Slide 3: Speaker: RJ Tesi MD CEO/CMO
www.roth.com Member: FINRA / SIPC 3 of 15 Speaker: RJ Tesi MD CEO/CMO Dr . Tesi has been President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015 . Dr . Tesi’s career in medicine and biopaharma has focused on strategies to manipulate th
Slide 4: INmune Bio Company Overview and Product Platforms
www.roth.com Member: FINRA / SIPC 4 of 15 INmune Bio Company Overview Product Platforms • Founded September 2015 • NASDAQ listed (INMB) • Simple capital structure • Multiple clinical programs • Strong IP portfolio • Identifiable near - term catalysts . • DN - TNF platform for treatment dysregulated
Slide 5: Company Overview Development Platforms
www.roth.com Member: FINRA / SIPC 5 of 15 Company Overview Development Platforms • Founded Sept 2015 • NASDAQ: INMB • Simple cap structure • Innate immune system focused • DN - TNF for CNS, immuno - oncology, COVID19 and metabolic diseases • INKmune – an NK cell focused platform targeting minimal re
Slide 6: Modifying the Catastrophic Complications of COVID19 by targeting the Master Cytokine with Quellor
www.roth.com Member: FINRA / SIPC 6 of 15 Modifying the Catastrophic Complications of COVID19 by targeting the Master Cytokine with Quellor A Phase II trial
Slide 7: What brings patients to the hospital with C19?
What brings patients to the hospital with C19? • Reality #1: At time of admission viral titer is decreasing • Reality #2: The dysregulated innate immune response to the virus causes Cytokine Storm • Problem: Cytokine Storm is making patients sick • Hypothesis: Blunting the effects of Cytokine Storm
Slide 8: TNF is the "Master Cytokine"
TNF is the “Master Cytokine” • TNF plays an outsize role in Cytokine Storm • sTNF stimulates IL1 and IL6 production • Removal of sTNF from “trio” decreases production of IL1 and IL6 • sTNF and IL1 activate endothelial cells, IL6 does not Quellor non - confidential October 2020 sTNF expression preced
Slide 9: The '3' pathologies of TNF in COVID-19
The ‘3’ pathologies of TNF in COVID - 19 1. Immune cell activation - activated cells produce cytokines 2. Endothelial cell activation – Up - regulation of ICAM/VCAM for transmigration of immune cells from blood vessel to tissue – Up - regulation of Tissue Factor to cause coagulopathy 3. Promotes inf
Slide 10: Quellor MOA
Quellor MOA see Steed et al., Science , 301, 2003 Receptor binding, Receptor binding, "small" domain (subunit A) Subunit A Receptor binding, (subunit A) Mutation Y87H (subunit C) Mutation R31C (for 10kD pegylation) "large" domain Subunit C Subunit B Mutation A145R Nonglycosylated small homotrimeric
Slide 11: Phase I experience - AD
Phase I experience - AD • Phase I oncology – ACTRN12618000675 224 – Safe and ↓CRP, CCL2, and IL6 • Phase I AD – NCT03943264 – On - going – reported preliminary data on 6 patients 13 July 2020 Quellor non - confidential October 2020 White Mater Free Water is a biomarker of neuroinflammation Dose resp
Slide 12: Phase II: Quellor to treat pulmonary complications of C19
Phase II: Quellor to treat pulmonary complications of C19 • Enrollment criteria: adult COVID19 infection with room air SaO2<94% – High risk comorbidities: age≥60; cardiovascular disease, obesity, diabetes, Black race or Hispanic ethnicity • Treatment groups: Standard - of - Care vs Standard - of - C
Slide 13: of
www.roth.com Member: FINRA / SIPC 13 of 15